SEATTLE, June 03, 2021, (MEDGADGET) — Overview
Still’s disease is a rare form of rheumatoid conditions. High spiking fever, joint swelling, muscle pain, sore throat, increased number of white cells (leukocytes, particularly neutrophils), and biological hepatitis are among the biological and clinical symptoms of this disorder. Still’s disease care can be divided into two categories: symptomatic medications and successful therapies. Effective medications are intended to treat the disorder more effectively to eradicate the disease’s symptoms, while symptomatic treatments may be started right away, even though the diagnosis has not been identified.
For instance, according to a study published in The American Journal of Medicine, Still’s disease treatment has primarily been based on retrospective evidence and case reports. Although mild cases of Still’s disease may be handled with nonsteroidal anti-inflammatory drugs (NSAIDs), over 80% of Still’s disease patients need corticosteroids and do not achieve remission. There is no such known risk factor that develops the Still’s disease, although there is no clear risk factor for developing Still’s disease, it is thought to be caused by an overabundance of IL-1 (Interleukin-1) in the body.
For More Information, Request Sample Copy Of Business Report: https://www.coherentmarketinsights.com/insight/request-pdf/4023
Growing demand for unique new therapies and the advent of drugs for Still’s disease are expected to propel the Still’s disease treatment market growth over the forecast period. For instance, as per the U.S. Food and Drug Administration (FDA), Canakinumab (Ilaris) can be indicated to all patients aged 2 years and above with Still’s disease.
Impact of Coronavirus (Covid-19) Pandemic
The COVID-19 epidemic has had a significant impact on the disease treatment market, as it is becoming increasingly difficult for researchers to perform research in this pandemic situation. The coronavirus is more likely to infect people who have rheumatic diseases like Still’s disease. Therefore, the majority of vendors are focusing their efforts on designing strategies to assist patients with Still’s disease in remaining agile amid the global disruptions caused by the COVID-19 pandemic. Furthermore, several political bodies around the world are making decisions such as new legislation in response to the current crisis.
The report’s detailed version would include the effects of COVID-19 as well as potential shifts in the industry’s future outlook, taking into account technical, social, political, and economic factors.
The Still’s disease treatment market is expected to be valued around US$ 1,539.4 million in 2020 and is estimated to rise at a CAGR around 4.49% over the forecast period (2020-2027).
Growing number of mergers & acquisitions strategies and drug releases is expected to drive growth of the Still’s disease treatment market over the forecast period.
Mergers and acquisitions are being used by major players in the industry to develop advanced drugs and therapies and introduce them in the Still’s disease treatment market. Rising number of drug releases in the market, is expected to drive growth of the Still’s disease treatment market and offer attractive growth opportunities in the Still’s disease treatment market over the forecast period. For instance, in July 2018, SOBI launched a third-line treatment, Kineret drug for the treatment of adult-onset Still’s disease (AOSD). When disease-modifying antirheumatic drugs (DMARDs) and corticosteroids have failed and methotrexate hasn’t worked, this new medication is recommended. Cryopyrin-associated intermittent syndromes (CAPS) and rheumatoid arthritis are currently treated with the drug in the U.K. (RA).
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/4023
Moreover, major players are concentrating on adoption of several strategies such as Merger & Acquisition to hold a significant position in the Still’s disease treatment market. For instance, in July 2019, Aevi Genomic Medicine entered into a license agreement with AstraZeneca for phase II trials of MEDI2338, which is a fully human mAb (monoclonal antibody) that targets IL-18 (interleukin 18). The company has planned to initially develop MEDI2338 for AOSD (adult-onset Still’s disease), which is a rare and orphan rheumatological disease with presently no approved biologic therapies in the U.S.
Lack of specific therapeutics for the condition of Still’s disease, is expected to hinder of the Still’s disease treatment market. For instance, Still’s disease is treated with anti-inflammatory medications including aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs). Cortisone pills, such as prednisone, are also used to treat the disease.
Moreover, growing number of generic therapeutics, product recalls, and the patent expiration of licensees and different drugs are expected to hinder growth of the Still’s disease treatment market.
Europe region valued for the highest share in the Still’s disease treatment market in 2019, due to the rising focus of major players on research & development activities and European Commission (EC) approvals in the market. For instance, in April 2018, Swedish Orphan Biovitrum AB announced that Kineret (anakinra) is approved by the EC for the treatment of Still’s disease. Kineret is used to treat Still’s disease in adults, teenagers, adolescents, and infants aged 8 months and above who weigh at least 10 kilogrammes. AOSD and SJIA with active systemic features of moderate to high disease activity are also included.
Moreover, the U.S. market following the same. For instance, the U.S. Food and Drug Administration (FDA) approved Novartis’ Ilaris injection for the treatment of active Still’s disease in June 2020. Treatment for Adult-Onset Still’s Disease is also included in this approval (AOSD). The Ilaris injection was previously approved for the treatment of SJIA (Systemic Juvenile Idiopathic Arthritis) in children aged 2 and above.
The Asia Pacific is expected to witness a significant growth in the global Still’s disease treatment market due to the various key players are taking initiatives and approvals for the treatment of adult still disease. For instance, in May 2019, Chugai Pharmaceutical Co., Ltd., a subsidiary of F. Hoffmann-La Roche Ltd, received expanded approval from the MHLA (Ministry of Health Labor and Welfare) in Japan for Actemra (tocilizumab) for the treatment of adult Still’s disease.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/stills-disease-treatment-market-3293
- By Treatment: Tocilizumab, Canakinumab, Anakinra, Pain Management, Corticosteroids Therapy, Other.
- By Route of Administration: Injectable, Oral.
- By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies.
Key players are dominating in the global Still’s disease treatment market such as Jubilant Life Sciences Ltd, AB2 Bio Ltd., Swedish Orphan Biovitrum AB, F. Hoffmann-La Roche Ltd, Novartis AG, Teva Pharmaceutical Industries Ltd, Vintage Labs, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd, Mylan N.V., Horizon Therapeutics plc, Dr Reddy’s Laboratories Ltd., Zydus Cadila, Fresenius Kabi AG and Amneal Pharmaceuticals LLC.
- Global Still’s Disease Treatment Market, By Treatment:
- Pain Management
- Corticosteroids Therapy
- Global Still’s Disease Treatment Market, By Route of Administration:
- Global Still’s Disease Treatment Market, By Distribution Channel:
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Global Still’s Disease Treatment Market, By Region:
- North America
- Asia Pacific
- Latin America
- Middle East
- Company Profiles
Other Exclusive Reports:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027